What are BTK Inhibitors? image

What are BTK Inhibitors?

Aug 13, 2025
01:30PM - 02:30PM EDT
Online Event
Overview

Join HealthTree for this webinar focusing on learning more about the family of therapies known as BTK Inhibitors which includes ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib.

 

 

Agenda
1:30 PM
Introduction
Dalton Bean

Dalton introduces the agenda of the event and featured speaker John Allan MD

1:35 PM
Presentation
John Allan MD

Dr. Allan talks about BTK inhibitors

2:05 PM
Questions and Answers
Dalton Bean

Type your questions in the chat, we will answer them!

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact John Allan MD

John Allan MD

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a B.S. in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University. Seeking an internal medicine residency program with particular strength in oncology, Dr. Allan moved to New York in 2009 to train at NewYork-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his hematology and medical oncology fellowship. Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology and is a member of the CLL Research Center.  Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.